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Background: Recombinant human B-type natriuretic peptide nesiritide should be assessed further, because different therapeutic regimen could 
induce different results. This study was to explore efficacy and safety of modified dose and administration regimen of nesiritide in elderly patients 
over 75 year suffering from acute heart failure (AHF).
Methods: 140 elderly patients over 75 year suffering from AHF were enrolled in. and randomly divided into two groups, conventional or nesiritide 
group. They were given conventional or conventional plus nesiritide treatment with a modified dose and continuous IV infusion regimen. The total 
dose of nesiritide 0.5~0.75 mg were continuous IV infused at a rate of 0.0075~0.015 /μg·kg / min for 10-15 hours once daily basing on a stable 
systolic blood pressure, the course of treatment was sustained for 13 days. During this time, the reflected efficacy and safety parameters were 
recorded.
Results: On Day 4, 8 and 14, medical research council (MRC) scales in nesiritide group were significantly lower than those in conventional 
group (P = 0.038, P= 0.015, P= 0.010). Scores of edema between two groups had no significant difference on Day 4 (P= 0.084), but were lower 
in nesiritide group on Day 8 and 14 (P=0.019, P= 0.003). Compared with conventional group, nesiritide group had much more net fluid losses on 
Day 4 and 8 (P=0.049, P=0.029), but difference disappeared on Day 14 (P=0.067). Serum creatinine had no significant difference on Day 4 and 
14 (P= 0.080, P= 0.063), but a slight and reversible rise was found on Day 8 in nesiritide group (P=0.029). There were not significantly different in 
systolic (P=0.190, P=0.585, P=0.162) and diastolic levels (P=0.228, P=0.940, P=0.772), serum NT-proBNP (P=0.914, P=0.851, P= 0.899) and cTnI 
(P=0.947, P=0.262, P= 0.629), 30 day (11.4 vs 10%, P=0.785) and 60 day(15.7 vs 17.1%, P=0.82) mortality between two groups in all courses.
Conclusions: Modified dose and administration regimen of nesiritide improved manifestation of congestion and had similar adverse effects 
compared with conventional treatment. In spite of no reduction on short-term mortality, nesiritide was still an important choice for those elderly with 
AHF even over 75 year.
